HLA-DPA1

Across TCGA pan-cancer cohorts, HLA-DPA1 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of HLA-DPA1’s most consistent transcriptional readouts.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where HLA-DPA1 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types HLA-DPA1 is over-expressed in tumor, although a few such as LSCC and COAD show the opposite, repressed pattern.

CCRCC, LSCC, and HNSC are the cancer types where HLA-DPA1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in HLA-DPA1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
CCRCC	Male	II,III,IV	+0.983	<.001	11	view →
LSCC	Male	II,III,IV	−0.874	<.001	8	view →
HNSC	Male	II,III,IV	+0.295	.001	8	view →
PDAC	All	All	+0.552	<.001	6	view →
COAD	All	III,IV	−0.294	.007	5	view →
OV	All	All	+0.592	.036	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

HLA-DPA1–CCRCC

Open the CCRCC breakdown →